144 related articles for article (PubMed ID: 35597298)
1. p53 missense mutant G242A subverts natural killer cells in sheltering mouse breast cancer cells against immune rejection.
Uddin MB; Roy KR; Hill RA; Roy SC; Gu X; Li L; Zhang QJ; You Z; Liu YY
Exp Cell Res; 2022 Aug; 417(1):113210. PubMed ID: 35597298
[TBL] [Abstract][Full Text] [Related]
2. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
4. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells.
Iannello A; Thompson TW; Ardolino M; Lowe SW; Raulet DH
J Exp Med; 2013 Sep; 210(10):2057-69. PubMed ID: 24043758
[TBL] [Abstract][Full Text] [Related]
5. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
Cho HM; Rosenblatt JD; Tolba K; Shin SJ; Shin DS; Calfa C; Zhang Y; Shin SU
Cancer Res; 2010 Dec; 70(24):10121-30. PubMed ID: 21159634
[TBL] [Abstract][Full Text] [Related]
6. Genetic Variability of Human Cytomegalovirus Clinical Isolates Correlates With Altered Expression of Natural Killer Cell-Activating Ligands and IFN-γ.
Galitska G; Coscia A; Forni D; Steinbrueck L; De Meo S; Biolatti M; De Andrea M; Cagliani R; Leone A; Bertino E; Schulz T; Santoni A; Landolfo S; Sironi M; Cerboni C; Dell'Oste V
Front Immunol; 2021; 12():532484. PubMed ID: 33897679
[TBL] [Abstract][Full Text] [Related]
7. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
8. Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells.
Tu MM; Mahmoud AB; Wight A; Mottashed A; Bélanger S; Rahim MM; Abou-Samra E; Makrigiannis AP
Cancer Res; 2014 Jul; 74(14):3684-94. PubMed ID: 24802191
[TBL] [Abstract][Full Text] [Related]
9. IQ Domain-Containing GTPase-Activating Protein 1 Regulates Cytoskeletal Reorganization and Facilitates NKG2D-Mediated Mechanistic Target of Rapamycin Complex 1 Activation and Cytokine Gene Translation in Natural Killer Cells.
Abel AM; Tiwari AA; Gerbec ZJ; Siebert JR; Yang C; Schloemer NJ; Dixon KJ; Thakar MS; Malarkannan S
Front Immunol; 2018; 9():1168. PubMed ID: 29892299
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2.
Li H; Lakshmikanth T; Garofalo C; Enge M; Spinnler C; Anichini A; Szekely L; Kärre K; Carbone E; Selivanova G
Cell Cycle; 2011 Oct; 10(19):3346-58. PubMed ID: 21941086
[TBL] [Abstract][Full Text] [Related]
11. MICA/IL-12: A novel bifunctional protein for killer cell activation.
Tietje A; Yang X; Yu X; Wei Y
Oncol Rep; 2017 Mar; 37(3):1889-1895. PubMed ID: 28098874
[TBL] [Abstract][Full Text] [Related]
12. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.
Mamessier E; Sylvain A; Bertucci F; Castellano R; Finetti P; Houvenaeghel G; Charaffe-Jaufret E; Birnbaum D; Moretta A; Olive D
Cancer Res; 2011 Nov; 71(21):6621-32. PubMed ID: 21937679
[TBL] [Abstract][Full Text] [Related]
13. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
14. CD4(+) NKG2D(+) T cells induce NKG2D down-regulation in natural killer cells in CD86-RAE-1ε transgenic mice.
Lin Z; Wang C; Xia H; Liu W; Xiao W; Qian L; Jia X; Ding Y; Ji M; Gong W
Immunology; 2014 Mar; 141(3):401-15. PubMed ID: 24708417
[TBL] [Abstract][Full Text] [Related]
15. Innate immune recognition of double-stranded RNA triggers increased expression of NKG2D ligands after virus infection.
Esteso G; Guerra S; Valés-Gómez M; Reyburn HT
J Biol Chem; 2017 Dec; 292(50):20472-20480. PubMed ID: 28986447
[TBL] [Abstract][Full Text] [Related]
16. The killing effect of Tanshinol on breast cancer cells: insight into the reversion of TGF-β1-mediated suppression of NK cell functions.
Yang C; Qian C; Zhang T; Zheng W; Zhang S; Wang S; Wang A; Zhao Y; Lu Y
Front Biosci (Landmark Ed); 2021 Nov; 26(11):1106-1118. PubMed ID: 34856757
[No Abstract] [Full Text] [Related]
17. Immune surveillance of unhealthy cells by natural killer cells.
Iannello A; Raulet DH
Cold Spring Harb Symp Quant Biol; 2013; 78():249-57. PubMed ID: 24135717
[TBL] [Abstract][Full Text] [Related]
18. Tumoral NKG2D alters cell cycle of acute myeloid leukemic cells and reduces NK cell-mediated immune surveillance.
Tang M; Acheampong DO; Wang Y; Xie W; Wang M; Zhang J
Immunol Res; 2016 Jun; 64(3):754-64. PubMed ID: 26740330
[TBL] [Abstract][Full Text] [Related]
19. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
